

## Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis.

### AUTHOR(S)

Sanjay H. Chotirmall, Catherine M. Greene, Noel G. McElvaney

### CITATION

Chotirmall, Sanjay H.; Greene, Catherine M.; McElvaney, Noel G. (2012): Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis.. Royal College of Surgeons in Ireland. Journal contribution. <https://hdl.handle.net/10779/rcsi.10784042.v1>

### HANDLE

[10779/rcsi.10784042.v1](https://hdl.handle.net/10779/rcsi.10784042.v1)

### LICENCE

CC BY-NC-SA 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact [repository@rcsi.com](mailto:repository@rcsi.com)

### URL

[https://repository.rcsi.com/articles/journal\\_contribution/Immune\\_inflammatory\\_and\\_infectious\\_consequences\\_of\\_estrogen\\_in\\_women\\_with\\_cystic\\_fibrosis\\_/10784042/1](https://repository.rcsi.com/articles/journal_contribution/Immune_inflammatory_and_infectious_consequences_of_estrogen_in_women_with_cystic_fibrosis_/10784042/1)

# **Immune, inflammatory and infectious consequences of estrogen in cystic fibrosis women**

*Chotirmall SH, Greene CM, McElvaney NG*

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Beaumont Road, Dublin 9, Ireland.

## **Introduction**

Cystic fibrosis (CF), a multi-system genetic disease with predominantly pulmonary manifestations, occurs due to defective chloride secretion at epithelial surfaces. The consequential sodium hyper-absorption leads to mucus hypersecretion, compromised mucociliary clearance and pathogenic colonization by, for instance, *Staphylococcus aureus* and/or *Pseudomonas aeruginosa*. This sequence of events leads to recurrent infection and persistent chronic neutrophilic inflammation causing airway damage, irreversible bronchiectasis, respiratory failure and death.

## **The CF gender gap**

Gender variation has long been recognized in CF: females have worse survival rates, poorer pulmonary function and earlier bacterial colonization (1-4). First reported in the early seventies, these observations appeared to lack explanation and have been controversial. However, published studies from the Canadian, Italian and United Kingdom registries support the existence of true gender disparities in CF survival (1, 4, 5). Although our understanding of CF pathophysiology and treatment interventions in CF improved hugely into the early 1990s leading to a doubling of the median survival age, notwithstanding such improvement, females continued to show poorer median survival, further evidence for genuine gender differences prompting ‘gender’ to be included in a CF survivorship model (2, 6).

It has been argued that individual centre practice should be reviewed if gender differences persist as lung function and nutrition are equivalent during childhood. However, the work upon which this recommendation is based was from a single centre that assessed pre-pubertal adolescents rather than adults, the group where genuine gender differences have been reported to exist (7). Interestingly, Italian registry data reported the absence of a gender gap in pre-pubertal children with CF (<16 years) but could not exclude gender differences if the cohort was followed into adulthood (8). Using a case mix adjustment method to overcome

problems comparing survival data from multiple sites, female gender was shown to be associated with an increased risk of death strengthening the argument for the existence of a true 'gender gap' (9). Data related to compliance suggests that age rather than gender are important factors for treatment adherence (10). A recent re-assessment of gender survival statistics including data from the Irish registry data have illustrated that whilst both genders have benefitted from exponential improvements to CF survival over time that female statistics remain inferior.

## **Estrogen**

During the course of a menstrual cycle, secretion of the major circulating estrogen, 17 $\beta$ -estradiol (E<sub>2</sub>), follows a cyclic, biphasic pattern with highest concentrations immediately preceding ovulation, thereafter levels fall rapidly. Female gender differences in CF may be related to hormones such as estrogen with emerging inflammatory, immune and microbiological data linked to E<sub>2</sub>. In view of its physiological role, fluctuating concentrations, and ability to modulate cellular functions, responses and gene expression E<sub>2</sub> represents an attractive avenue for investigation in terms of the gender differences observed in CF disease. This prompted our investigation of its role in the CF gender gap (11, 12).

## **The immune and inflammatory consequences of estrogen exposure in the CF airway**

The adverse clinical phenotype in females with CF is initially noted at puberty where E<sub>2</sub> concentrations gradually rise and secondary sexual characteristics develop. This is unsurprising as prior work illustrates that estrogens dehydrate the airway surface liquid (ASL) by increasing ENaC expression (13) while the severity of *P. aeruginosa* pneumonia worsens in the presence of E<sub>2</sub> through enhancement of Th17 inflammation and depletion of lactoferrin (14). *In vivo* nasal potential differences (NPDs) vary with menstrual cycling; such data are suggestive of direct associations between systemic hormonal concentration, disease manifestations and innate immune function (15, 16) and provide evidence of the hormonal influence on both inflammation and immune function. Investigating toll-like receptor (TLR) agonist induced IL-8 release in CF airway epithelial cells we found E<sub>2</sub> could dose-dependently inhibit this effect which is controlled by NF- $\kappa$ B. The estrogen receptor (ER) isoform mediating this response was ER $\beta$ , which, incidentally is also the predominant ER within the CF airway. The mechanism involved increased the expression of secretory leucoprotease inhibitor (SLPI), an NF- $\kappa$ B inhibitor. SLPI knockdown abrogated the

inhibitory effect of E<sub>2</sub> (17). Together these data suggest a hypo-responsive innate immune response in the CF lung during times of high E<sub>2</sub> exposure. This would be deleterious during times of exacerbation when robust, rapid innate immune responses are required. In tandem with a diminished ASL height and impaired antimicrobial defences we suggest this explains, in part, why females with CF do worse.

### **The microbial endocrine effects of estrogen in cystic fibrosis**

Females acquire and convert to the more aggressive mucoid phenotype of *P. aeruginosa* ahead of males leading to poorer clinical outcomes, again without explanation. *P. aeruginosa* converts to mucoidy through alginate production. Alginate biosynthesis is controlled by the *mucA*-*algT* operon which encode the sigma factor AlgT and its inhibitor MucA, and the *algD* operon and remotely located *algC* gene which encode the alginate biosynthetic machinery. Mutations in *mucA* are a major cause of mucoid conversion. Defective MucA fails to inhibit AlgT allowing it to promote transcription of genes within the *algD* operon. We showed that E<sub>2</sub> selected for mutations in *mucA*, through increases in H<sub>2</sub>O<sub>2</sub> and catalase inhibition (18). To further probe the link between E<sub>2</sub>, infective exacerbations and mucoidy in CF females, we conducted a prospective clinical study and detected a significant relationship between *in vivo* E<sub>2</sub> concentrations and exacerbations with the majority occurring during the proliferative phase of the menstrual cycle, a stage of the highest *in vivo* E<sub>2</sub> concentrations (18). Utilizing Irish registry data, we discovered that those on the oral contraceptive pill (OCP) trended toward requiring reduced numbers of antibiotic courses however proper assessment of this potential therapy would require a well powered double blind placebo controlled trial.

### **Future directions and therapeutic prospects**

Our group has demonstrated the multifaceted effects of high circulating E<sub>2</sub> states in the female CF airway. First, its anti-inflammatory effects through an ER $\beta$ -mediated upregulation of SLPI, causing a TLR hyporesponsiveness to a range of bacterial agonists and an inhibition of IL-8 release (17). Second, its microbial endocrine effects in the promotion of mucoid conversion of *P. aeruginosa* by selection for *mucA* mutations. Thirdly, we have confirmed its association with infective exacerbations and report initial observations of decreased antibiotic requirements in CF females using the OCP (18). These findings provide the basis for several interesting concepts to consider in the context of the reported gender

differences in CF. With respect to E<sub>2</sub>-mediated TLR hyporesponsiveness when taken together with the compromised ASL known to occur in high circulating E<sub>2</sub> states (16), this could create an environment for a particular two week time period each month for CF females where they will be prone to both acquisition of infection and a subsequent compromised response to it (17). As a consequence, the context and timing of administration of an anti-inflammatory agent in CF requires careful thought particularly in the context of females during high circulating E<sub>2</sub> states.

Whilst ER $\beta$  specific agonists may represent a potential anti-inflammatory candidate to emerge from our work its development for safe clinical use remains a pharmacological challenge. Whilst E<sub>2</sub> was shown to influence SLPI expression, its effects on other antimicrobials have yet to be clearly established in a CF setting. Most morbidity and mortality in CF is attributed to the uncontrolled chronic inflammatory environment within the CF lung associated with an exuberant influx of inflammatory cells. It is plausible to suggest, in addition to IL-8, that other cytokines may be influenced by E<sub>2</sub> and its effects on neutrophils, monocytes, their receptors and response to pathogens would also be worth future exploration.

The interaction between E<sub>2</sub> and *P. aeruginosa* advances the field of microbial endocrinology which to date has solely described effects of the stress (adrenaline, noradrenaline) but not sex hormones (estrogen, testosterone) on microorganisms. Our findings in relation to *P. aeruginosa* may be extrapolated beyond CF to other clinical states involving this organism for instance immunocompromised hosts, non-CF bronchiectatics in the premenopausal population or patients with immunodeficiency syndromes. Further work may also be performed to assess the effects of E<sub>2</sub> on other organisms such as *Staphylococcus* or *Burkholderia spp*, both important in CF. The role of fungi continues to emerge in CF and the impact of E<sub>2</sub> on fungi such as *Aspergillus* or *Candida spp*. are areas for future study.

## **Perspectives**

The *in vivo* link between systemic E<sub>2</sub> and infective exacerbations in CF females provide novel insight into female CF disease. Whether the majority or a specific subset of “hormone responsive” CF females exist that illustrate a disease course of recurrent exacerbations linked with hormonal variation remains to be established. It could be that a group of CF females have disease that fluctuates over the course of a menstrual cycle comparable to that observed in “catamenial asthmatics”. Identification of such women would

be crucial in permitting intervention to modulate endogenous E<sub>2</sub> levels and theoretically lessen the risk of exacerbations. Avenues to modify endogenous E<sub>2</sub> concentrations include the use of antiestrogens such as Tamoxifen. Whilst *in vitro* data has shown positive effects on ASL (16), clinical use of this agent remains a remote possibility owing to its negative effect on growth and unacceptable side effect profile in the CF setting. A safer option would be the use of the OCP to modulate endogenous E<sub>2</sub> concentrations. We observed lower requirements for antibiotics in CF females using the OCP compared to those that were not. It is not clear whether these benefits are a property of exogenous estrogen or that of the much lower endogenous E<sub>2</sub> concentrations that are observed in those taking the pill. Our initial observations with OCP use in CF warrant a formal double blind placebo controlled clinical study to assess the estrogen-based OCP as a potential treatment option for CF exacerbations before it can be routinely recommended. Future work should assess different CF cohorts and account for the various OCP subtypes and E<sub>2</sub> concentrations contained within them. In addition to recording infection frequency and antibiotic usage, such studies if possible should obtain NPDs and measure ASL. Recording lung function data would also be important. Overall, E<sub>2</sub> impacts upon the inflammatory, immune and infectious process within the CF female airway and at least in part accounts for the gender dichotomy observed in CF disease that until now remained unexplained.

## References

1. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. *Am J Epidemiol.* 1996;143(10):1007-17.
2. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. *Am J Epidemiol.* 1997 May 1;145(9):794-803.
3. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. *Jama.* 2005;293(5):581-8.
4. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. *Eur Respir J.* 2007;29(3):522-6.
5. Bossi A BF, Braggion C, Magno, E. C., Cosimi, A., de Candussio, G., Gagliardini, R., Giglio, L., Giunta, A., Grzincich, G. L., La Rosa, M., Lombardo, M., Lucidi, V., Manca, A., Mastella, G., Moretti, P., Padoan, R., Pardo, F., Quattrucci, S., Raia, V., Romano, L., Salvatore, D., Taccetti, G., Zanda, M. [Italian Cystic Fibrosis Registry: 10 years of activity]. *Epidemiol Prev.* 1999;23(1):5-16.
6. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. *Am J Epidemiol.* 2001;153(4):345-52.
7. Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? *Chest.* 2005 Oct;128(4):2824-34.
8. Viviani L BA, Assael BM. Absence of a gender gap in survival. An analysis of the Italian registry for cystic fibrosis in the paediatric age. *J Cyst Fibros.* 2011;10(5):313-7.
9. O'Connor G.T QHB, Kahn R., Robichaud P., Maddock J., Lever T., Detzer M., Brooks J.G. Case-mix adjustment for evaluation of mortality in cystic fibrosis. *Pediatr Pulmonol.* 2002;33(2):99-105.
10. Masterson T.L. WBG, Newberry B.H., Omlor G.J. Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis. *Pediatr Pulmonol.* 2010;21:21.
11. Kulich M. RM, Goss C.H., Wilmott R. Improved survival among young patients with cystic fibrosis. *J Pediatr.* 2003;142(6):631-6.
12. Jackson AD, Daly L, Jackson AL, Kelleher C, Marshall BC, Quinton HB, et al. Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis. *Thorax.* 2011 Aug;66(8):674-9.
13. Sweezey NB, Ghibu F, Gagnon S, Schotman E, Hamid Q. Glucocorticoid receptor mRNA and protein in fetal rat lung in vivo: modulation by glucocorticoid and androgen. *Am J Physiol.* 1998 Jul;275(1 Pt 1):L103-9.
14. Wang Y, Cela E, Gagnon S, Sweezey NB. Estrogen aggravates inflammation in *Pseudomonas aeruginosa* pneumonia in cystic fibrosis mice. *Respir Res.* 2010;11:166.
15. Sweezey NB, Smith D, Corey M, Ellis L, Carpenter S, Tullis DE, et al. Amiloride-insensitive nasal potential difference varies with the menstrual cycle in cystic fibrosis. *Pediatr Pulmonol.* 2007 Jun;42(6):519-24.
16. Coakley RD, Sun H, Clunes LA, Rasmussen JE, Stackhouse JR, Okada SF, et al. 17beta-Estradiol inhibits Ca<sup>2+</sup>-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. *J Clin Invest.* 2008 Dec;118(12):4025-35.
17. Chotirmall SH, Greene CM, Oglesby IK, Thomas W, O'Neill SJ, Harvey BJ, et al. 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. *Am J Respir Crit Care Med.* 2010;182(1):62-72.
18. Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O'Neill SJ, et al. Effect of estrogen on *pseudomonas mucoidy* and exacerbations in cystic fibrosis. *N Engl J Med.* 2012 May 24;366(21):1978-86.